Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Axitinib + nivolumab is a combination regimen of two agents: axitinib, an oral small molecule tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and nivolumab, a monoclonal antibody that targets the programmed death 1 (PD-1) immune checkpoint on T cells. Used together, they synergistically inhibit angiogenesis (tumor blood vessel growth) and enhance T-cell mediated anti-tumor immune response. This combination is under investigation and clinical use, particularly in metastatic renal cell carcinoma (mRCC) and in other advanced solid tumors, especially after progression on other therapies. The mechanistic rationale includes direct tumor growth suppression by VEGFR inhibition and activation of cytotoxic immune responses by PD-1 blockade.
- Brand names
- Inlyta + Opdivo
- Other names
- Axitinib plus NivolumabNivolumab plus Axitinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on axitinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + nivolumab.